Earnings season brings clarity—and volatility. The biopharmaceutical sector is already providing a glimpse into what to expect, with several companies releasing preliminary results and 2026 guidance. Krystal Biotech (KRYS) is leading the pack, while Day One Biopharmaceuticals (DAWN) faces investor scrutiny.
Krystal Biotech (KRYS) reported preliminary unaudited 2025 VYJUVEK revenue of approximately $389 million, fueling a 5.02% surge in the stock. The company also boasts impressive cash reserves of $955 million. This strong performance underscores the potential of rare disease therapies and positions Krystal Biotech for continued growth. Investors are clearly optimistic about the company's strategic vision and its ability to capitalize on the unmet needs in the rare disease space.
Day One Biopharmaceuticals (DAWN), on the other hand, saw its stock dip 3.35% despite announcing a 172% year-over-year increase in preliminary 2025 OJEMDA net product revenue. The company also provided 2026 U.S. guidance, projecting revenue between $225 million and $250 million. While the revenue growth is significant, the market's reaction suggests that investors may be concerned about future profitability or competition in the pediatric cancer treatment market.
Meanwhile, Kura Oncology (KURA) announced $2.1 million in initial KOMZIFTI sales and secured a $195 million milestone. KURA closed down slightly at -1.47%. As earnings season progresses, attention will remain focused on companies' ability to not only meet but exceed expectations, and to provide clear and compelling guidance for the year ahead. The SPY is up 0.66% to $694.07 as earnings season begins.